---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 6, 2016

Rexahn Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Registrant’s telephone number, including area code:  (240) 268-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

 

Section 7

– Regulation FD

Item 7.01

Regulation FD Disclosure.

On July 6, 2016, Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Lisa Nolan, Ph.D., to serve as Chief Business Officer of the Company.   In this role, Dr. Nolan will be responsible for leading the Company’s business development programs and providing strategic guidance for the Company.

On July 11, 2016, the Company issued a press release announcing the appointment of Dr. Nolan.  A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Section 9

– Financial Statements and Exhibits

Item 9.01

Financial Statements and Exhibits.

(d)          Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit Index

---